Personalis, Inc. (PSNL)

Market Cap	63.13M
Revenue (ttm)	73.48M
Net Income (ttm)	-108.30M
Shares Out	50.50M
EPS (ttm)	-2.25
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	147,216
Open	1.280
Previous Close	1.300
Day's Range	1.180 - 1.280
52-Week Range	0.891 - 2.600
Beta	1.95
Analysts	Strong Buy
Price Target	5.50 (+340.0%)
Earnings Date	May 8, 2024

About PSNL

Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal res...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jun 20, 2019
• Employees: 223
• Stock Exchange: NASDAQ
• Ticker Symbol: PSNL

Financial Performance

In 2023, Personalis's revenue was $73.48 million, an increase of 12.97% compared to the previous year's $65.05 million. Losses were -$108.30 million, -4.43% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for PSNL stock is "Strong Buy." The 12-month stock price forecast is $5.5, which is an increase of 340.00% from the latest price.

Price Target

$5.5

(340.00% upside)

Analyst Consensus: Strong Buy